OptiNose, Inc. (OPTN)
NASDAQ: OPTN · Real-Time Price · USD
9.17
+0.02 (0.22%)
Mar 31, 2025, 4:00 PM EDT - Market closed
OptiNose Employees
OptiNose had 132 employees as of December 31, 2023. The number of employees decreased by 9 or -6.38% compared to the previous year.
Employees
132
Change (1Y)
-9
Growth (1Y)
-6.38%
Revenue / Employee
$592,621
Profits / Employee
-$163,189
Market Cap
92.36M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OPTN News
- 10 days ago - OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN - Business Wire
- 10 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders - GlobeNewsWire
- 11 days ago - Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - GlobeNewsWire
- 11 days ago - Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 2 months ago - Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million - GlobeNewsWire
- 3 months ago - Optinose Announces 1-for-15 Reverse Stock Split - GlobeNewsWire
- 4 months ago - Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript - Seeking Alpha